For how we live.
ESO-T01 builds cancer-killing T cells inside the body, skipping the cell harvest and chemo prep normal CAR-T needs. All four responded — but the cells faded, and median progression-free survival was 4 months.
Registries show a real but narrow signal: a few cancers, led by prostate and thyroid, run high in 9/11 responders, while overall cancer incidence sits at or below the rate expected.
Zenbexus didn't have to outlive patients in a control arm to win approval — it had to clear their bone marrow of detectable disease faster. That shortcut is becoming the norm, not the exception.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
In the MajesTEC-9 trial, the bispecific antibody teclistamab cut the risk of progression or death by 71% against standard three- and two-drug regimens. Serious infections were common.